OR WAIT null SECS
September 01, 2020
Oxford Biomedica will reserve capacity for AstraZeneca in three of its manufacturing suites in its new commercial manufacturing center, Oxbox, for 18 months.
August 26, 2020
The contract is valued at $106.3 million and is supported by Operation Warp Speed.
The European Commission (EC) and Moderna have concluded exploratory talks on the potential purchase of Moderna’s COVID-19 vaccine candidate for Europeans.
August 24, 2020
Catalent will manufacture drug substance for AZD1222 at its Harmans, MD facility.
The Phase II trial is a randomized, placebo-controlled, observer-blinded study that will include patients aged 18 to 84 years.
August 20, 2020
EC finalizes agreement to purchase millions of doses of AstraZeneca's COVID-19 vaccine.
Novavax has signed an agreement with the UK government for 60 million doses of a COVID-19 vaccine and a Phase III clinical trial.
August 19, 2020
Plastic primary packaging could help prevent supply chain shortages associated with high demand for COVID-19 vaccines.
August 13, 2020
SK bioscience will manufacture the vaccine antigen component for use in the final drug product at its vaccine facility in Andong L-house, South Korea.
In combination with BARDA’s previous award, the commitment for early access to Moderna’s vaccine candidate has now reached to up to $2.48 billion.